Low cerebrospinal fluid somatostatin in Parkinson disease

Dupont, E.; Christensen, Søren; Hansen, Anders Melchior; Olivarius, Bent de Fine; Şrskov, Hans

doi:10.1212/wnl.32.3.312

Cited by 117 publications

(33 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our finding of particularly low levels of SLI in the CSF of patient with parkinsonism is in agreement with earlier reports [9,11]. In one study, however, no signifi cant decrease of SLI was observed [3], and it was sug gested that SLI levels are reduced only in parkinsonian patients with dementia [4], In support of this, decreases of cerebral cortical SLI were observed only in PD pa tients with dementia but not in those without dementia [1], In this study no correlation between the presence or absence of dementia and the SLI concentration is noted, the small size of the group, however, precludes a gener alization.…”

Section: Discussionsupporting

confidence: 94%

“…In patients with Parkinson's disease (PD) sub stantial decreases of somatostatin-like immunoreactivity (SLI) were observed in the CSF by several research groups [9,11] while no significant alteration was found by another [4], Marked decreases of CSF SLI were also reported in patients with Alzheimer's disease or senile dementia of Alzheimer type (SDAT) [8,20,27], In SDAT [10] as well as in PD [1,8] cerebral levels of the neuropeptide substance P (SP) were also decreased albeit to a lesser degree. Anatomic, biochemical and pharma cological studies have associated SP-ergic activity with dopaminergic neurons in the substantia nigra and the striatum [13,14,17] raising the issue of a possible involvement of SP in PD.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immunoreactive Substance P and Somatostatin in the Cerebrospinal Fluid of Senile Parkinsonian Patients

et al. 1989

View full text Add to dashboard Cite

The concentration of substance-P-like immunoreactivity (SPLI) and somatostatin-like immunoreactivity (SLI) in the lumbar spinal fluid of senile parkinsonian patients (mean age 77.6 ± 6.7 years) and senile control patients (mean age 83.5 ± 5.6 years) were determined by specific radioimmunoassays. Mean SPLI and SLI levels in the control group were 8.1 ± 2.0 (SD) and 32.5 ± 12.0 fmol/ml, respectively. The mean SPLI levels were not significantly different in the groups. The mean SLI level was significantly lower in the group of patients with Parkinson’s disease (19.8 ± 9.0 fmol/ml). A comparison with results in patients with senile dementia of Alzheimer type (SDAT) shows that, in addition to clinical and pathological correlations, Parkinson’s disease of late onset may share a deficit in somatostatinergic neuromodulation with SDAT.

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Introductionmentioning

confidence: 99%

Immunoreactive Substance P and Somatostatin in the Cerebrospinal Fluid of Senile Parkinsonian Patients

et al. 1989

View full text Add to dashboard Cite

show abstract

“…Similarly, in PD there is evidence of decrease of SLI in the cortex of demented patients and reduced SLI in the CSF (Dupont et al, 1982;Jolkkonen et al, 1986;Beal et al, 1986). Our demented PD patients showed slightly lower SLI than non-demented, but not significantly, possibly due to predominantly mild dementia.…”

Section: Discussionsupporting

confidence: 60%

Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls

Hartikainen¹,

Reinikainen²,

Soininen³

et al. 1992

J Neural Transm Gen Sect

View full text Add to dashboard Cite

Several neurotransmitter markers were investigated in the cerebrospinal fluid (CSF) from patients with Alzheimer's disease (AD) (n = 27), Parkinson's disease (PD) (n = 35) and ALS (n = 26) and from control subjects (n = 34) to compare the possible alterations in the biochemical profiles of these different neurodegenerative diseases. The main proportion of the patients represented an early phase of the illness at the time of the diagnosis. Correlations of the degree of dementia and the stage of the disease with CSF measures were evaluated. The CSF levels of somatostatin like-immunoreactivity (SLI) were significantly reduced in AD patients when compared with those of normals and ALS patients. The CSF concentrations of homovanillic acid (HVA) were significantly decreased for PD patients and the decrease focused on the non-demented patients. A trend of decreasing HVA values towards the most advanced stage of Parkinson's disease assessed by Webster's scale was also displayed. The content of 3-methoxy-4-hydroxyphenylglycol (MHPG) in the CSF was higher for ALS patients than for other groups. The lowest 5-hydroxy-indoleacetic acid (5HIAA) levels were observed in the PD group and the lowest acetylcholinesterase (AChE) activities were found in the PD patients with the most severe disease. Changes in CSF measures were too subtle to be beneficial for diagnostic purposes, but adequate for reflecting the different neurochemical profiles of these three degenerative neurological disorders.

show abstract

“…In patients with PD, a reduced brain level of somatostatin (SOM) is frequently observed (3)(4)(5)(6)(7). In old Wistar rats, an inhibition of brain SOM receptors can produce catalepsy (8), an animal model of parkinsonian bradykinesia and rigidity.…”

Section: Introductionmentioning

confidence: 99%

Histamine Potentiates Cyclosomatostatin-Induced Catalepsy in Old Rats

Ionov¹,

Turgeneva²

2015

Avicenna J Neuro Psych Physio

View full text Add to dashboard Cite

Background:The decreased level of somatostatin and increased level of histamine are detected in the Parkinsonian brain. In old Wistar rats, the brain somatostatin deficiency can initiate catalepsy that suggests the pathogenic significance of this abnormality in Parkinson's disease (PD). The ability of histamine to affect the somatostatin deficiency action is not studied. Objectives: The current study aimed to examine if histamine alters the cataleptogenic activity of the brain somatostatin deficiency in Wistar rats. Materials and Methods:The animals used in the study were 100 -110 and 736 -767 days old. Catalepsy was evaluated by the bar test. The inhibition of the brain somatostatin activity was simulated by I.C.V. administration of cyclosomatostatin (cycloSOM), a somatostatin receptor antagonist. Results: CycloSOM (0.2, 1.0, and 5.0 µg) and histamine (1.0 and 10.0 µg) alone were ineffective in both young and old animals. In combination, however, cycloSOM and histamine initiated cataleptic response in old rats. Effect of the combination was inhibited by H1 and H2 but not H3 antagonists. Conclusions: CycloSOM and histamine synergistically exert catalepsy in old rats. In light of these data, the combination of the decreased brain level of somatostatin and increased brain level of histamine may be of pathogenic relevance for extrapyramidal signs in PD.

show abstract

Low cerebrospinal fluid somatostatin in Parkinson disease

Cited by 117 publications

References 0 publications

Immunoreactive Substance P and Somatostatin in the Cerebrospinal Fluid of Senile Parkinsonian Patients

Immunoreactive Substance P and Somatostatin in the Cerebrospinal Fluid of Senile Parkinsonian Patients

Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls

Histamine Potentiates Cyclosomatostatin-Induced Catalepsy in Old Rats

Contact Info

Product

Resources

About